AstraZeneca Takes Stake in Cambridge Antibody Technology alongside Antibody Discovery Alliance
Business Review Editor
Abstract
AstraZeneca and Cambridge Antibody entered into a strategic alliance for the joint discovery and development of human monoclonal antibodies in the field of inflammatory and respiratory diseases.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.